[go: up one dir, main page]

ES2532850T3 - Uso terapéutico de al menos una neurotoxina botulínica en el tratamiento del dolor inducido por al menos un agente anticanceroso - Google Patents

Uso terapéutico de al menos una neurotoxina botulínica en el tratamiento del dolor inducido por al menos un agente anticanceroso Download PDF

Info

Publication number
ES2532850T3
ES2532850T3 ES07866446.3T ES07866446T ES2532850T3 ES 2532850 T3 ES2532850 T3 ES 2532850T3 ES 07866446 T ES07866446 T ES 07866446T ES 2532850 T3 ES2532850 T3 ES 2532850T3
Authority
ES
Spain
Prior art keywords
botulinum neurotoxin
treatment
anticancer agent
therapeutic use
pain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES07866446.3T
Other languages
English (en)
Inventor
Christine Favre
Michel Auguet
Pierre-Etienne Chabrier De Lassauniere
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ipsen Pharma SAS
Original Assignee
Ipsen Pharma SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ipsen Pharma SAS filed Critical Ipsen Pharma SAS
Application granted granted Critical
Publication of ES2532850T3 publication Critical patent/ES2532850T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Utilización de al menos una neurotoxina botulínica para la obtención de un medicamento destinado a tratar o prevenir el o los dolores post-quimioterapia mediante administración localizada por vía intramuscular, intradérmica o subcutánea que permite obtener un efecto generalizado, no siendo el o los dolores dolor(es) inducido(s) por tumores.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6

Claims (1)

  1. imagen1
ES07866446.3T 2006-10-27 2007-10-26 Uso terapéutico de al menos una neurotoxina botulínica en el tratamiento del dolor inducido por al menos un agente anticanceroso Active ES2532850T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0609435 2006-10-27
FR0609435A FR2907680B1 (fr) 2006-10-27 2006-10-27 Utilisation therapeutique d'au moins une neurotoxine botulique dans le traitement de la douleur induite par au moins un agent anti-cancereux
PCT/FR2007/001773 WO2008059126A1 (fr) 2006-10-27 2007-10-26 Utilisation therapeutique d'au moins une neurotoxine botulique dans le traitement de la douleur induite par au moins un agent anti-cancereux

Publications (1)

Publication Number Publication Date
ES2532850T3 true ES2532850T3 (es) 2015-04-01

Family

ID=38109619

Family Applications (1)

Application Number Title Priority Date Filing Date
ES07866446.3T Active ES2532850T3 (es) 2006-10-27 2007-10-26 Uso terapéutico de al menos una neurotoxina botulínica en el tratamiento del dolor inducido por al menos un agente anticanceroso

Country Status (13)

Country Link
US (1) US8273359B2 (es)
EP (1) EP2083837B1 (es)
JP (1) JP5386359B2 (es)
CN (1) CN101541336B (es)
CA (1) CA2667128C (es)
DK (1) DK2083837T3 (es)
ES (1) ES2532850T3 (es)
FR (1) FR2907680B1 (es)
HK (1) HK1137352A1 (es)
PL (1) PL2083837T3 (es)
PT (1) PT2083837E (es)
RU (1) RU2483747C2 (es)
WO (1) WO2008059126A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7780967B2 (en) * 2000-02-08 2010-08-24 Allergan, Inc. Reduced toxicity Clostridial toxin pharmaceutical compositions
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
FR2889936B1 (fr) * 2005-09-01 2007-12-21 Sod Conseils Rech Applic Methode pour quantifier une neurotoxine cholinergique dans un echantillon
FR2902341B1 (fr) * 2006-06-16 2011-02-25 Scras Utilisation therapeutique simultanee, separee ou etalee dans le temps d'au moins une neurotoxine botulique, et d'au moins un derive opiace
US9278133B2 (en) * 2006-10-27 2016-03-08 The Chemo-Sero-Therapeutic Research Institute Highly purified type A botulinum toxin preparation from infant botulism pathogen
FR2907680B1 (fr) * 2006-10-27 2012-12-28 Scras Utilisation therapeutique d'au moins une neurotoxine botulique dans le traitement de la douleur induite par au moins un agent anti-cancereux
FR2910327B1 (fr) * 2006-12-22 2013-04-26 Scras Utilisation d'au moins une neurotoxine botulique pour traiter la douleur induite par les traitements therapeutiques du virus du sida.
FR2930447B1 (fr) 2008-04-25 2010-07-30 Sod Conseils Rech Applic Utilisation therapeutique d'au moins une neurotoxine botulique dans le traitement de la douleur dans le cas de la neuropathie diabetique
US20100332337A1 (en) * 2009-06-25 2010-12-30 Bullock Roddy Mckee Universal one-click online payment method and system
DK2854840T3 (en) 2012-05-30 2018-03-05 Harvard College MANIPULATED BOTULINUM NEUROTOXIN
ES2642916T3 (es) * 2014-06-06 2017-11-20 Galit KLEINER-FISMAN Toxina botulínica para su uso en el tratamiento de la paratonia
EP3274364B1 (en) 2015-03-26 2021-08-04 President and Fellows of Harvard College Engineered botulinum neurotoxin
CN113968921B (zh) 2016-02-19 2024-04-05 艾利丹尼森公司 用于加工粘合剂和相关组合物的两阶段方法
CN110072880B (zh) 2016-08-24 2025-02-18 哈佛大学校长及研究员协会 工程化肉毒杆菌神经毒素
US10640595B2 (en) 2016-10-25 2020-05-05 Avery Dennison Corporation Controlled architecture polymerization with photoinitiator groups in backbone
EP3728361B1 (en) 2017-12-19 2023-01-18 Avery Dennison Corporation Post-polymerization functionalization of pendant functional groups
US20230165812A1 (en) * 2020-02-27 2023-06-01 President And Fellows Of Harvard College Nociceptor neurons control cancer immunosurveillance

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69435302D1 (de) * 1993-12-28 2010-08-26 Allergan Inc Neurotoxisches Komponent eines Botulinumtoxins zur Behandlung von Spätdyskinesie
DE19501266A1 (de) * 1995-01-18 1996-07-25 Madaus Ag Verfahren zur Herstellung von Flavano-Lignan-Zubereitungen mit verbesserter Freisetzung und Resorbierbarkeit danach erhältliche Zubereitungen und deren Verwendung zur Herstellung von Arzneimitteln
SE9803239D0 (sv) * 1998-09-24 1998-09-24 Diabact Ab Composition for the treatment of acute pain
US6113915A (en) * 1999-10-12 2000-09-05 Allergan Sales, Inc. Methods for treating pain
US6139845A (en) * 1999-12-07 2000-10-31 Allergan Sales, Inc. Method for treating cancer with a neurotoxin
US7780967B2 (en) * 2000-02-08 2010-08-24 Allergan, Inc. Reduced toxicity Clostridial toxin pharmaceutical compositions
US20060269575A1 (en) * 2000-02-08 2006-11-30 Allergan, Inc. Botulinum toxin pharmaceutical compositions formulated with recombinant albumin
DK1398038T4 (da) * 2000-02-08 2011-03-28 Allergan Inc Lægemidler med botulinustoxin
US6464986B1 (en) * 2000-04-14 2002-10-15 Allegan Sales, Inc. Method for treating pain by peripheral administration of a neurotoxin
US20020192239A1 (en) * 2001-01-09 2002-12-19 Borodic Gary E. Use of botulinum toxin for the treatment of chronic facial pain
KR20030018827A (ko) 2001-08-31 2003-03-06 서구일 Ａ형 보툴리눔 독소를 유효성분으로 포함하는 신경차단제,및 이를 이용한 교감신경절 차단의 적응질환 치료제
CA2369810C (en) * 2002-01-30 2007-08-07 1474791 Ontario Limited Method of treating pain
US20040009180A1 (en) * 2002-07-11 2004-01-15 Allergan, Inc. Transdermal botulinum toxin compositions
US20050152905A1 (en) * 2002-08-22 2005-07-14 Omoigui Osemwota S. Method of biochemical treatment of persistent pain
WO2004075832A2 (en) * 2003-02-27 2004-09-10 Lucas John M Methods and compositions for the treatment of chronic pain using dhea and derivatives thereof
US20040247623A1 (en) * 2003-03-24 2004-12-09 Roger Cady Method and article for treatment of sensory neuron related disorders through transdermal application of botulinum toxin
US7270287B2 (en) * 2004-01-06 2007-09-18 Allergan, Inc. Botulinum toxin treatment for kinesia
GB2417419A (en) 2004-07-12 2006-03-01 Ipsen Ltd Therapeutic use of Botulinum toxin
GB2419526A (en) 2004-10-28 2006-05-03 Ipsen Ltd Pharmaceutical composition containing botulinum neurotoxin
GB2416692A (en) 2004-08-04 2006-02-08 Ipsen Ltd Pharmaceutical composition containing botulinum neurotoxin
WO2006042249A2 (en) * 2004-10-08 2006-04-20 Neuromolecular Pharmaceuticals, Inc. Methods and compositions for treating migraine pain
CA2597244A1 (en) * 2005-03-03 2006-09-14 Universite Catholique De Louvain Methods and compositions for the treatment of cancer
US20090214466A1 (en) * 2005-05-09 2009-08-27 Levin Bruce H Methods of Alleviating Disorders and Their Associated Pain
KR100726441B1 (ko) * 2005-11-22 2007-06-11 삼성전자주식회사 현상장치 및 이를 이용한 화상형성장치
FR2902341B1 (fr) 2006-06-16 2011-02-25 Scras Utilisation therapeutique simultanee, separee ou etalee dans le temps d'au moins une neurotoxine botulique, et d'au moins un derive opiace
FR2907680B1 (fr) * 2006-10-27 2012-12-28 Scras Utilisation therapeutique d'au moins une neurotoxine botulique dans le traitement de la douleur induite par au moins un agent anti-cancereux
FR2910327B1 (fr) * 2006-12-22 2013-04-26 Scras Utilisation d'au moins une neurotoxine botulique pour traiter la douleur induite par les traitements therapeutiques du virus du sida.
FR2930447B1 (fr) * 2008-04-25 2010-07-30 Sod Conseils Rech Applic Utilisation therapeutique d'au moins une neurotoxine botulique dans le traitement de la douleur dans le cas de la neuropathie diabetique

Also Published As

Publication number Publication date
HK1137352A1 (en) 2010-07-30
FR2907680A1 (fr) 2008-05-02
JP5386359B2 (ja) 2014-01-15
CA2667128A1 (fr) 2008-05-22
EP2083837A1 (fr) 2009-08-05
RU2009120021A (ru) 2010-12-10
CN101541336B (zh) 2012-12-19
PL2083837T3 (pl) 2015-06-30
EP2083837B1 (fr) 2015-01-07
DK2083837T3 (en) 2015-03-23
US8273359B2 (en) 2012-09-25
WO2008059126A1 (fr) 2008-05-22
CN101541336A (zh) 2009-09-23
US20100068231A1 (en) 2010-03-18
CA2667128C (fr) 2017-08-29
RU2483747C2 (ru) 2013-06-10
FR2907680B1 (fr) 2012-12-28
JP2010507635A (ja) 2010-03-11
PT2083837E (pt) 2015-03-26

Similar Documents

Publication Publication Date Title
ES2532850T3 (es) Uso terapéutico de al menos una neurotoxina botulínica en el tratamiento del dolor inducido por al menos un agente anticanceroso
AR126205A2 (es) Métodos de uso de linfocitos infiltrantes de tumor en melanoma doble refractario
BR112021016169A2 (pt) Composições compreendendo 5-metóxi-n,n-dimetiltriptamina (5-meo-dmt) para uso no tratamento de transtornos mentais
CO2021000174A2 (es) Composiciones tópicas para el alivio del dolor
CL2017003436A1 (es) Compuestos de benzoxacepina oxazolidinona y métodos de uso
AR068862A1 (es) Terapia de combinacion de un anticuerpo anti- cd20 de tipo ii con un agente activo anti- bcl-2
CL2008001268A1 (es) Compuestos derivados de n-[6-amino-5-aril-piridin-2-il]-carboxamida; composicion farmaceutica que los comprende; composicion farmaceutica combinada que los comprende junto a otro agente farmacologico adicional; y uso de los mismos en el tratamiento del dolor.
BR112018003985A2 (pt) macrociclos peptidomiméticos e usos dos mesmos
NI200800169A (es) Uso de derivados de sulfamidas heterocíclicas benzo-fusionadas para el tratamiento del dolor
BR112015026006A2 (pt) métodos para o tratamento de câncer com o uso de terapia de combinação com inibidor de cinase tor
CU23821A3 (es) Composición farmacéutica que comprende una difenilurea sustituida con omega-carboxiarilo para el tratamiento del cáncer
CO7101246A2 (es) Compuesto de carbamato y preparación y uso de los mismos
DOP2012000290A (es) 4-yodo-3-nitrobenzamida en combinacion con agentes anti-tumorales para el uso en el tratamiento de cancer utero y cancer de ovario
CL2008001743A1 (es) Uso de un compuesto derivado de quinazolina para tratar el cancer; uso del compuesto y de otro compuesto antineoplasico; compuestos derivados de quinazolina; y composicion farmaceutica que los comprende.
MX2017000627A (es) Metodos para tratar pacientes con hipercolesterolemia familiar heterocigota (hfhe).
CL2011000916A1 (es) Uso de una combinacion de un inhibidor de proteasoma epoxicetona peptidica o una sal farmaceutica aceptable del mismo, y uno o mas de otros agentes terapeuticos para tratar el cancer.
UY30158A1 (es) Uso de derivados de benzo-heteroaril sulfamida para el tratamiento del dolor
AR105712A1 (es) Composiciones de insulina de rápida acción
AR092899A1 (es) Uso de masitinib para el tratamiento del cancer en subpoblaciones de pacientes identificados que utilizan factores de prediccion
ES2604586T3 (es) Uso terapéutico de la neurotoxina botulínica de Tipo A en el tratamiento del dolor asociado a la neuropatía diabética
AR070025A1 (es) Uso de derivados de 1-amino-alquilciclohexano para el tratamiento del tinnitus coclear y composicion farmaceutica
MX2017000628A (es) Metodos para tratar pacientes de alto riesgo cardiovascular con hipercolesterolemia.
CL2011000798A1 (es) Uso de etexilato de dabigatran o una sal del mismo para preparar un medicamento util para la prevencion del ictus en pacientes que padecen fibrilacion auricular.
BR112015026247A2 (pt) métodos para o tratamento de câncer com o uso de terapia combinada com inibidor de cinase tor
CL2011002766A1 (es) Compuestos derivados de carboxamida, inhibidores de calpaina; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades neurodegenerativas, alzahimer, dolor, entre otras.